Brief: Revive Therapeutics Provides Update Of Novel Bucillamine Formulation Development
11/10/2023 13:54
Oct 11 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE OF NOVEL BUCILLAMINE
FORMULATION DEVELOPMENT
Source text for Eikon: ID:nGNX6qNdSq
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure